European Roll Out For Samsung Bioepis's Etanercept Biosimilar
This article was originally published in PharmAsia News
After gaining two regulatory approvals for its biosimilars at home last year, South Korea's Samsung Bioepis has now received its first overseas clearance for an etanercept biosimilar, in Europe. Benepali, which will be Europe's first biosimilar version of the fusion protein, is set to enter 31 European markets.
You may also be interested in...
After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.
As the prolonged COVID-19 pandemic continues to take a toll globally, South Korean pharma firms’ overseas drug development activities are increasingly being disrupted by the impact.